272 related articles for article (PubMed ID: 36775284)
1. Aducanumab for the treatment of Alzheimer's disease: a systematic review.
Rahman A; Hossen MA; Chowdhury MFI; Bari S; Tamanna N; Sultana SS; Haque SN; Al Masud A; Saif-Ur-Rahman KM
Psychogeriatrics; 2023 May; 23(3):512-522. PubMed ID: 36775284
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer disease neuropathology in a patient previously treated with aducanumab.
Plowey ED; Bussiere T; Rajagovindan R; Sebalusky J; Hamann S; von Hehn C; Castrillo-Viguera C; Sandrock A; Budd Haeberlein S; van Dyck CH; Huttner A
Acta Neuropathol; 2022 Jul; 144(1):143-153. PubMed ID: 35581440
[TBL] [Abstract][Full Text] [Related]
3. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
Budd Haeberlein S; Aisen PS; Barkhof F; Chalkias S; Chen T; Cohen S; Dent G; Hansson O; Harrison K; von Hehn C; Iwatsubo T; Mallinckrodt C; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; Skordos L; Tian Y; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A
J Prev Alzheimers Dis; 2022; 9(2):197-210. PubMed ID: 35542991
[TBL] [Abstract][Full Text] [Related]
4. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis.
Jeremic D; Navarro-López JD; Jiménez-Díaz L
Ageing Res Rev; 2023 Sep; 90():102012. PubMed ID: 37423541
[TBL] [Abstract][Full Text] [Related]
6. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
[TBL] [Abstract][Full Text] [Related]
7. Aducanumab-Hope or Disappointment for Alzheimer's Disease.
Wojtunik-Kulesza K; Rudkowska M; Orzeł-Sajdłowska A
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901797
[TBL] [Abstract][Full Text] [Related]
8. Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid.
Lin L; Hua F; Salinas C; Young C; Bussiere T; Apgar JF; Burke JM; Kandadi Muralidharan K; Rajagovindan R; Nestorov I
CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):362-372. PubMed ID: 35029320
[TBL] [Abstract][Full Text] [Related]
9. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
Vaz M; Silva V; Monteiro C; Silvestre S
Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
Ross EL; Weinberg MS; Arnold SE
JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
[TBL] [Abstract][Full Text] [Related]
11. Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
Chen T; O'Gorman J; Castrillo-Viguera C; Rajagovindan R; Curiale GG; Tian Y; Patel D; von Rosenstiel P; von Hehn C; Salloway S; Hock C; Nitsch RM; Haeberlein SB; Sandrock A; Singhal P
Alzheimers Dement; 2024 May; 20(5):3406-3415. PubMed ID: 38567735
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
Qiao Y; Gu J; Yu M; Chi Y; Ma Y
CNS Drugs; 2024 Mar; 38(3):169-192. PubMed ID: 38429615
[TBL] [Abstract][Full Text] [Related]
13. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
Avgerinos KI; Ferrucci L; Kapogiannis D
Ageing Res Rev; 2021 Jul; 68():101339. PubMed ID: 33831607
[TBL] [Abstract][Full Text] [Related]
14. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
[TBL] [Abstract][Full Text] [Related]
15. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
[TBL] [Abstract][Full Text] [Related]
16. Aducanumab: The first targeted Alzheimer's therapy.
Yang P; Sun F
Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
[TBL] [Abstract][Full Text] [Related]
17. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro S; Valeri A; Mazzon E
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
[TBL] [Abstract][Full Text] [Related]
18. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
[TBL] [Abstract][Full Text] [Related]
19. Aducanumab for the treatment of Alzheimer's disease.
Tagliapietra M
Drugs Today (Barc); 2022 Oct; 58(10):465-477. PubMed ID: 36305541
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
